2016 American Urological Association Annual Meeting

Bladder Cancer

Atezolizumab in Platinum-Treated Advanced Urothelial Carcinoma: A New Standard of Care?

Compared with a historic control rate, a phase II study of the programmed cell death ligand 1 (PD-L1) inhibitor atezolizumab (Tecentriq) has demonstrated clinically meaningful responses in patients wi...

Prostate Cancer

Chemotherapy After Radical Prostatectomy May Benefit African Americans and High-Risk Patients

A new U.S. Department of Veterans Affairs (VA) study suggests that African American men and men with a higher tumor stage may benefit from adjuvant chemotherapy following radical prostatectomy.1 Accor...